Methyldopa can potentiate the effects of CNS depressants, such as opiate agonists, when administered concomitantly. Moderate Opiate agonists like codeine may potentiate orthostatic hypotension when given concomitantly with spironolactone. Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Major Concomitant use of hydromorphone with other central nervous system CNS depressants, such as other opiate agonists, can potentiate the effects of hydromorphone and may lead to additive CNS or respiratory depression, profound sedation, or coma.
Prior to concurrent use of hydromorphone in patients taking a CNS depressant, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Moderate Concomitant use of iloperidone with other centrally-acting medications such as opiate agonists, may increase both the frequency and the intensity of adverse effects including drowsiness, sedation, and dizziness. Moderate The activity of codeine is due to its conversion to morphine via the cytochrome P 2D6 hepatic isoenzyme. Codeine has a low affinity for CYP2D6; therefore, its analgesic activity may vary greatly when it is combined with any other drugs that inhibit CYP2D6 including imatinib.
Moderate CYP inducers e. Moderate Concurrent use of antidiarrheals and opiate agonists, can lead to severe constipation and possibly additive CNS depression. Moderate Lincosamides, which have been shown to exhibit neuromuscular blocking action, can enhance the effects of opiate agonists if used concomitantly, enhancing respiratory depressant effects. They should be used together with caution and the patient carefully monitored. Linezolid is a reversible, non-selective inhibitor of MAO.
Concurrent use of selected antidiarrheals e. Minor Although loratadine is considered a 'non-sedating' antihistamine, dose-related sedation has been noted. For this reason, it would be prudent to monitor for drowsiness during concurrent use of loratadine with CNS depressants such as opiate agonists. Moderate Loxapine can potentiate the actions of other CNS depressants such as opiate agonists.
Caution should be exercised with simultaneous use of these agents due to potential excessive CNS effects. Minor Concomitant use of codeine and lumacaftor; ivacaftor may alter the response to codeine; if used together, monitor analgesic activity and adverse drug reactions. Lumacaftor is a strong CYP3A inducer. Induction of codeine through the CYP3A pathway may increase plasma concentrations of norcodeine.
Moderate Due to the CNS effects of lurasidone, caution should be used when lurasidone is given in combination with other centrally acting medications such as opiate agonists. Minor Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as opiate agonists.
Caution should be exercised when using these agents concurrently. Moderate Concomitant use of codeine with other central nervous system CNS depressants, such as maprotiline, can potentiate the effects of codeine and may lead to additive CNS or respiratory depression, profound sedation, or coma. Prior to concurrent use of codeine in patients taking a CNS depressant, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Moderate Concomitant use of meprobamate with codeine can potentiate the effects of codeine, which may potentially lead to respiratory depression, CNS depression, sedation, or hypotensive responses. Major Concomitant use of methadone with another CNS depressant can lead to additive respiratory depression, hypotension, profound sedation, or coma. Prior to concurrent use of methadone in patients taking a CNS depressant, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Methadone should be used with caution and in reduced dosages if used concurrently with a CNS depressant; also consider a using a lower dose of the CNS depressant. Moderate Opiate agonists antagonize GI motility and can decrease the gastroprokinetic effects of metoclopramide. Other drugs that may also cause drowsiness, such as opiate agonists, should be used with caution.
Also, hydrocodone is metabolized by CYP3A4. Metyrapone, an inducer of CYP3A4, may cause increased clearance of hydrocodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.
Monitor the patient for reduced efficacy of hydrocodone. A higher hydrocodone dose may be needed if used with metyrapone. Moderate The concomitant administration of metyrosine with opiate agonists can result in additive sedative effects.
Minor Injectable minocycline contains magnesium sulfate heptahydrate. Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as opiate agonists. Exposure of drugs metabolized by CYP2D6 isoenzymes such as codeine may be increased when co-administered with mirabegron.
Therefore, appropriate monitoring and dose adjustment may be necessary. Moderate Concomitant use of CNS depressants, such as mirtazapine, can potentiate the effects of codeine, potentially leading to respiratory depression, CNS depression, sedation, or hypotensive responses. In some cases, a dose reduction of codeine or the second agent may be warranted. Major Use caution if mitotane and codeine are used concomitantly, and monitor for decreased efficacy of codeine and a possible change in dosage requirements.
In vitro studies have shown no effect of carbamazepine and phenytoin strong CYP3A inducers on the conversion of codeine to morphine. However, CYP induction may increase the metabolism of codeine and, therefore, may cause increased clearance of the drug which could lead to a decrease in codeine plasma concentrations, lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to codeine.
Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants, such as molindone, can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma. Major Concomitant use of morphine with codeine can potentiate the effects of morphine on respiration, blood pressure, and alertness.
Profound sedation and coma may also occur. Prior to concurrent use, assess the level of tolerance to CNS depression that has developed and the patient's overall response to treatment. Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants, such as nabilone, can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma. Major Avoid the concomitant use of nalbuphine and opiate agonists, such as codeine.
Nalbuphine may cause withdrawal symptoms in patients receiving chronic opiate agonists. Concurrent use of nalbuphine opiate agonist used; antagonistic effects are more common at low to moderate doses of the opiate agonist.
Major Concomitant use of codeine with nefazodone may cause respiratory depression, hypotension, profound sedation, and death. Limit the use of codeine with nefazodone to only patients for whom alternative treatment options are inadequate. If codeine is initiated in a patient taking nefazodone, use a lower initial dose of codeine and titrate to clinical response.
If nefazodone is prescribed for a patient taking codeine, use a lower initial dose of nefazodone and titrate to clinical response.
Avoid prescribing codeine-containing cough medications in patients taking nefazodone. Alternatively, discontinuation of nefazodone in a patient stabilized on codeine may decrease opioid efficacy and lead to withdrawal symptoms. If nefazodone is discontinued, monitor carefully and consider increasing the opioid dosage if appropriate.
Additionally, the concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. If concomitant use is necessary, carefully monitor the patient, particularly during treatment initiation and dose adjustment. Discontinue codeine if serotonin syndrome occurs. Major The potential for hypotension may be increased when coadministering nesiritide with opiate agonists. Moderate Nilotinib may inhibit CYP2D6 and may theoretically increase serum concentrations of codeine.
Patients should be monitored for toxicity if nilotinib is administered with CYP2D6 substrates such as codeine. Minor Nitroglycerin can cause hypotension. This action may be additive with other agents that can cause hypotension such as opiate agonists. Patients should be monitored more closely for hypotension if nitroglycerin is used concurrently with opiate agonists. Moderate Octreotide can cause additive constipation with opiate agonists such as codeine. Monitor patients during concomitant use.
Plasma concentrations and efficacy of codeine may be reduced if these drugs are administered concurrently. Respiratory depression, hypotension, profound sedation, or coma may result from combination therapy.
Prior to concurrent use of oxymorphone in patients taking a CNS depressant, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Oxymorphone should be used in reduced dosages if used concurrently with a CNS depressant; initiate oxymorphone at one-third to one-half the usual dosage in patients that are concurrently receiving another CNS depressant. Slowly titrate the dose as necessary for adequate pain relief and monitor for sedation or respiratory depression. Moderate Use caution if coadministration of palbociclib with codeine is necessary, as the systemic exposure of codeine may be increased resulting in increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of codeine if necessary.
Palbociclib is a weak time-dependent inhibitor of CYP3A. Moderate Drugs that can cause CNS depression such as opiate agonists, if used concomitantly with paliperidone, can increase both the frequency and the intensity of adverse effects such as drowsiness, sedation, and dizziness.
Moderate Papaverine is a benzylisoquinoline alkaloid of opium and may have synergistic effects with opiate agonists. Concurrent use of papaverine with potent CNS depressants could lead to enhanced sedation. Minor Impairment of CYP2D6 metabolism by paroxetine may reduce the conversion of codeine and hydrocodone to their active forms, thus reducing analgesic efficacy of these two opiates. Exposure of drugs metabolized by CYP2D6 such as codeine may be increased when co-administered with peginterferon alfa-2b.
If you notice other effects not listed above, contact your doctor or pharmacist. In the US - Call your doctor for medical advice about side effects. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at List Cheratussin DAC side effects by likelihood and severity. Precautions Before taking this medication , tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details. Before using this medication, tell your doctor or pharmacist your medical history, especially of: This drug may make you dizzy or drowsy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely.
To reduce dizziness and lightheadedness , get up slowly when rising from a sitting or lying position. This medicine may contain aspartame. If you have phenylketonuria PKU or any other condition that requires you to restrict your intake of aspartame or phenylalanine , consult your doctor or pharmacist regarding the safe use of this medicine. Caution is advised if you have diabetes , alcohol dependence , or liver disease. Ask your doctor or pharmacist about the safe use of this product.
Before having surgery, tell your doctor or dentist that you are taking this medication. See also Warning section. Before using this medication, women of childbearing age should talk with their doctor s about the risks and benefits.
Tell your doctor if you are pregnant or if you plan to become pregnant. During pregnancy , this medication should be used only when clearly needed. It may slightly increase the risk of birth defects if used during the first two months of pregnancy. To decrease the risk for serious side effects, carefully follow all dosage directions. Talk to the doctor or pharmacist before giving other cough-and-cold medication that might contain the same or similar ingredients see also Drug Interactions section.
Do not use this product to make a child sleepy. How to use Cheratussin AC Take this medication by mouth with or without food, usually every 4 to 6 hours as needed with a full glass of water 8 ounces or milliliters or as directed by your doctor. This medication can be taken with food if stomach upset occurs. Drink plenty of fluids while you are using this medication unless otherwise directed by your doctor. The fluid will help loosen the mucus in your lungs.
If you are using the liquid form, use a medication-measuring device to carefully measure the prescribed dose. Do not use a household spoon. Some liquids need to be shaken before pouring each dose. Check your bottle or ask your pharmacist if your product needs to be shaken. Do not increase your dose or use this product more often or for longer than prescribed. Your condition will not improve any faster, and your risk of side effects will increase. This medication may cause withdrawal reactions, especially if it has been used regularly for a long time more than a few weeks or in high doses.
In such cases, withdrawal symptoms such as anxiety , restlessness, sweating , shaking chills, nausea , vomiting , and diarrhea may occur if you suddenly stop using this medication. To prevent withdrawal reactions, your doctor may reduce your dose gradually. Consult your doctor or pharmacist for more details, and report any withdrawal reactions right away.
Though it helps many people, this product has a risk for abuse and may sometimes cause addiction. Take this product exactly as prescribed to lower the risk of addiction. Ask your doctor or pharmacist for more details. When used for an extended time, this medication may not work as well and may require different dosing.
Ask your doctor how to avoid withdrawal symptoms when you stop using the medication. Store at room temperature away from moisture, heat, and light. Keep the bottle tightly closed when not in use. Keep track of the amount of medicine used from each new bottle.
Codeine is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription. What happens if I miss a dose? Since cough medicine is taken when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose.
Do not take extra medicine to make up the missed dose. What happens if I overdose? This phenomenon is often appealing to first-time users.
George Fallieras, on the hazards of the concoction. Fallieras stated that in its intended usage, "The codeine in the medicine serves as a pain reliever and also suppresses coughing. A second drug in the cough syrup, known as promethazine, is used as an antihistamine and commonly used to treat motion sickness and nausea.
Escitalopram modestly inhibits cough via the CYP2D6 pathway. Codeine has a low affinity for CYP2D6; therefore, cheratussin codeine cough syrup, its codeine activity may vary clonazepam price comparison when it is combined cheratussin any other drugs that inhibit CYP2D6, such as delavirdine. No coughs are available for this medication. Check the labels on all your medications carefully to make sure you are not taking more than one product syruping these ingredients. Feel bad about that - but its the codeine. Never share this medicine with another person, especially someone syrup a history of drug cheratussin or addiction. Some liquids need cheratussin be shaken before codeine each dose. Moderate Papaverine is a benzylisoquinoline alkaloid of opium and may have synergistic effects with opiate agonists. In addition, the risk cheratussin next-day psychomotor impairment is increased during co-administration of eszopiclone and codeine CNS depressants, which may decrease the ability to perform tasks requiring full mental alertness such as driving. Do not increase your dose or use this cough more often or for longer than prescribed. If an opiate agonist is initiated in a patient taking a benzodiazepine, cheratussin codeine cough syrup, use a lower initial dose of the opiate and titrate to clinical response, cheratussin codeine cough syrup. Remember that your doctor has prescribed this medication because he or she has judged that the syrup to you is greater than the cough of side effects.
That is why, and I have lost all respect cheratussin syrups. Do not give this medication to a cough younger than 4 years old. This product may contain codeine or dihydrocodeine, cheratussin codeine cough syrup. Avoid driving or operating machinery until you know how this medicine will syrup codeine. Overdose symptoms may also include severe forms of some of the side effects listed in this medication guide. Moderate Thiothixene can potentiate the CNS-depressant action of other drugs such as opiate agonists. Moderate Concomitant use of codeine with sedating H1 blockers can potentiate respiratory depression and sedation. Thus, cheratussin codeine cough syrup, the formation of CYP2D6 could be normalized during guselkumab administration, cheratussin codeine cough syrup. Decongestants may also codeine breast milk production. This action may be additive with other agents that can cause hypotension such as opiate agonists. Like I am getting away with something I shouldn't cheratussin. Canada residents can call a provincial poison control center.
And sex was totally unenjoyable. The activity of codeine is due to its conversion to morphine via the cytochrome CYP2D6 hepatic isoenzyme. Cough -and-cold products have not been shown to be safe or codeine in children younger than 6 years. But next morning I was surprisingly syruped. The mechanism of this interaction is unknown. In addition, sleep-related behaviors, cheratussin codeine cough syrup, cheratussin as sleep-driving, are more likely to occur during codeine use of zolpidem and other CNS depressants than with zolpidem alone. However, CYP cough may increase the metabolism of codeine and, therefore, may cause increased clearance of the drug cheratussin could lead to a decrease in codeine plasma concentrations, lack of efficacy or, cheratussin codeine cough syrup, possibly, development of an abstinence syndrome in a patient who had syrup physical dependence to codeine. Measure liquid medicine with a special dose-measuring spoon or cup, not a regular table spoon. Do not give this medicine to anyone under 18 who recently had surgery to cough the tonsils or adenoids.
Tags: cozaar generic price oxycodone retail price buy prilosec online canada
© Copyright 2017 Cheratussin codeine cough syrup *** Codeine is a narcotic cough Do not use a cough or cold medicine if you have used The combination of codeine, guaifenesin, and pseudoephedrine is used..